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Abstract: Genetic variants are considered as one of the main determinants of the 
concentration of serum lipids and coronary artery disease (CAD). Polymorphisms 
in the Apolipoprotein (Apo) AI-CIII-AIV gene cluster has been known to affect the 
concentrations of various lipid sub-fractions and the risk of CAD. The present study 
assessed associations between polymorphisms of the Apo AI-CIII-AIV gene cluster, 
[ApoA-I,-75G > A, (rs1799837); ApoC-III 3238C > G, (SstI), (rs5128) and ApoA-IV, 
Thr347Ser(347A > T), (rs675)] with serum lipids and their contributions to CAD in 
North Indian population. We recruited age, sex matched, 200 CAD patients and 200 
healthy controls and tested them for fasting levels of serum lipids. We genotyped 
selected polymorphisms using polymerase chain reaction-restriction fragment 
length polymorphism. There were no statistically significant association of selected 
polymorphisms (or their combinations) with CAD even after employing additive, 
dominant and recessive models. However there was significant association of se-
lected polymorphisms with various lipid traits amongst the control cohort (p < 0.05). 
Mean levels of high density lipoprotein cholesterol and triglycerides were found to 
be significantly higher among controls carrying at least one mutant allele at ApoA1-
75G > A (p = 0.019) and ApoCIII SstI (p < 0.001) polymorphism respectively. Our 
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study observed that the selected polymorphisms in the ApoAI-CIII-AIV gene cluster 
although significantly affect various lipid traits but this affect does not seem to 
translate into association with CAD, at least among North Indian population.
Subjects: Genetics; Human Biology; Lipidology; Medical Genetics; Atherosclerosis; Vascular 
Medicine
Keywords: apolipoprotein (Apo) AI-CIII-AIV gene cluster; single nucleotide polymorphisms 
(SNPs); serum lipids; coronary artery disease (CAD); linkage disequilibrium, haplotypes
1. Introduction
Coronary artery disease (CAD) accounts for roughly one half of all cardiovascular deaths and is a 
major cause of morbidity and mortality around the world. Both genetic and environmental factors 
play a crucial role in the causation of CAD. Current evidences suggest that positive family history of 
CAD and different alterations in lipid metabolism, including high low density lipoprotein cholesterol 
(LDL-c) and low high density lipoprotein cholesterol (HDL-c) levels (both separately and jointly), high 
triglyceride (TG) levels, high apoB levels, high lipoprotein (a) (Lp(a)) levels, are important risk factors 
for CAD. The lipid abnormalities significantly contribute to the risk of developing premature CAD. 
These lipid abnormalities also have genetic determinants (Sankaranarayanan, Chakraborty, & 
Boerwinkle, 1999). One of the commonly studied lipid gene cluster is the Apolipoprotein (Apo) AI-
CIII-AIV gene cluster (Agrawal & Mastana, 2014). This group of genes is located on chromosome 
11q23–q24. Several polymorphic forms of the genes in this cluster not only can alter plasma levels 
of various lipids but can affect expression of other genes and/or modulate the action of different 
proteins within the human body, which can lead to higher chance of developing premature CAD.
ApoA-I, which is mainly synthesized in the liver and the small intestine, is an obligatory activator 
of lecithin cholesterol acyltransferase (LCAT). It is a major apolipoprotein component of HDL-c, and 
is known to promote cholesterol efflux from macrophages and return it to the liver for excretion, a 
process commonly known as “reverse cholesterol transport” (Lewis & Rader, 2005). HDL-c can also 
prevent lipoprotein oxidation, exert anti-inflammatory actions in vitro, and promote cell proliferation 
and survival which contributes to its anti-atherogenic effects (Barter et al., 2004). This inverse rela-
tionship between plasma HDL-c levels and coronary atherosclerotic events has been demonstrated 
consistently by several epidemiologic studies which validates its anti-atherogenic properties. Genetic 
regulation of the concentrations of plasma levels of HDL-c and apoA-I are well established as a re-
sult of several twin and family studies, which have reported the heritability of HDL-c concentration 
to be around 40% (Pulkkinen, Viitanen, Kareinen, Lehto, & Laakso, 2000; Ordovas et al., 2002). Inter-
individual variations in plasma ApoA1 and HDL are proven to be largely influenced by a common 
polymorphism of a guanine (G) to adenine (A) substitution (G/A) at −75 bp (rs1799837), in the pro-
moter region of the ApoA1 gene (Jeenah, Kessling, Miller, & Humphries, 1990; Wang, Badenhop, 
Humphrey, & Wilcken, 1996). Non-association of HDL-c with Apo A1-75G > A polymorphism has also 
been reported in some studies, these contradictory results could be a result of an intricate interplay 
of various environmental and ethnic factors (Ordovas et al., 2002).
The liver and intestine also jointly synthesize the ApoC-III protein. Although the precise function 
of ApoC-III is not completely understood, there is increasing evidence that this apolipoprotein is as-
sociated with the catabolism of triglyceride-rich lipoproteins (TGRL). Animal studies have shown that 
ApoC-III acts as an inhibitor of the lipoprotein lipase-mediated hydrolysis of TGRL (Jong, Hofker, & 
Havekes, 1999), thus possibly regulating plasma triglyceride (TG) levels. A Cytosine (C) to Guanine (G) 
substitution at 3,238 bp (rs5128) in the ApoC-III gene (also known as SstI polymorphism) has been 
extensively studied in relation to various lipid traits. Several studies have reported an association 
between S2 allele of SstI polymorphism and elevated TG levels (Paul-Hayase et al.,1992; Rees et al., 
1985) while others reported no association with TG levels (Price, Morris, Burgon, Donald, & 
Kitchin,1986; Marcil et al., 1996).
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The precise physiological role of ApoA-IV is also not completely understood, but numerous in vitro 
studies suggest that ApoA-IV participates in several steps of “reverse cholesterol transport” by bind-
ing to peripheral cells, promoting cholesterol efflux and enhancing the formation of small HDL par-
ticles by activating LCAT (Steinmetz & Utermann, 1985). In addition, it is suggested that ApoA-IV 
and may negatively influence lipid absorption and chylomicron assembly thus modulating body 
weight gain (Weinberg, 2002). Published literature suggests that Apo A-IV may also have antioxi-
dant properties. Taken together, these evidences suggests that ApoA-IV may be considered as an 
anti-atherogenic factor as lower plasma levels of ApoA-IV has already been proven to be risk factor 
for atherogenic events (Kronenberg et al., 2000). A common Adenine (A) to Thymine (T) substitution 
at 347 bp in the ApoA-IV gene (also known as 347A > T, Thr347Ser polymorphism) has been shown 
to be associated with lower plasma levels of Apo AIV and higher incidences of CAD in some studies 
(Wong et al., 2003).
Several other common polymorphisms have been identified in the APOAI-CIII-AIV gene cluster, 
e.g. XmnI (C−2500T), and MspI (C + 83T) in Apo-AI gene (Kessling, Horsthemke, & Humphries, 1985; 
Paulweber, Friedl, Krempler, Humphrie, & Sandhofer, 1988; Wang et al., 1996). T−455C; in Apo CIII 
gene (Dammerman, Sandkuijl, Halaas, Chung, & Breslow,1993; Groenendijk et al., 1999), PstI poly-
morphism in the Apo AI-CIII intragenic region (Vavatsi et al., 1995) and Gln360His in Apo AIV gene 
(Kretowski et al., 2006) have been studied for their effect on various lipid traits and contribution to 
CAD. APOAI-CIII-AIV gene cluster polymorphisms that we aimed to study, i.e. Apo AI-75G > A poly-
morphism, Apo CIII- SstI polymorphism and Apo AIV-Thr347Ser polymorphism are among the impor-
tant ones and studies of these loci among Indians populations are limited (Singh, Singh, Gaur, & Kaur, 
2007; Singh, Singh, Kaur, & Grewal, 2008). Moreover, except for few sporadic studies, the distributions 
of apolipoprotein polymorphisms have mainly been studied in European populations, the results of 
which may or may not translate among Indians. Also, it is well known that differences among popula-
tions in the relative frequency of susceptibility genotypes or environmental exposure will contribute 
to differences in the utility of a genotype for predicting a trait within a particular population.
Our primary objective therefore was to test the association between polymorphisms of the APOAI-
CIII-AIV gene cluster, namely: (i) Apo AI-75G > A polymorphism; (rs1799837), (ii) the ApoC-III 
3238C > G polymorphism (SstI polymorphism); (rs5128) and (iii) 347A > T polymorphism (also known 
as Thr347Ser polymorphism); (rs675) in ApoA-IV gene on plasma levels of various lipid traits and 
their role in the pathogenesis of CAD among North Indian population from Uttar Pradesh (UP).
2. Materials and methods
2.1. Subjects
This study was carried out by departments of Cardiology and Medical Genetics at Sanjay Gandhi Post 
Graduate Institute of Medical Sciences (SGPGIMS), Lucknow, India in collaboration with School of 
Sport Exercise and Health Sciences, Loughborough University, Leicestershire, UK. The study was ap-
proved by local ethics committees of SGPGIMS, Lucknow and Loughborough University.
We prospectively included 200 proven CAD patients and 200 healthy case controls in the present 
study after obtaining the written informed consent. Proven CAD was defined as the detection of at 
least 50% or more stenosis in one or more native coronary arteries of the patient, verified through 
coronary angiography. Patients who experienced even a single symptom of rest angina during last 
6 weeks were excluded. Demographics, anthropometrics and clinical history of all subjects were col-
lected using a uniform clinical proforma. Diabetes, hypertension, smoking and family history of pre-
mature CAD was determined in the subjects as per standard definitions. The healthy controls 
included in the present study were sex matched and had no known history of ischemic heart disease, 
endocrine or metabolic disorders. They were selected after administration of an exercise cardiac 
stress test (treadmill test) or a physiologic stress test (Dobutamine Stress echocardiogram) to ne-
gate the possibility of an underlying CAD. All selected cases and controls were of North Indian eth-
nicity and were residents of Uttar Pradesh, since last five generations.
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Three millilitres of EDTA whole blood was collected for DNA extraction. DNA was extracted from 
whole blood by using commercially available Qiagen kits (QIAamp DNA Mini Kit; QiagenInc. Valencia, 
CA USA) as per the manufacturers protocol.
2.2. Lipid estimations
Three millilitres of fasting blood from each subject was drawn for lipid profile. Direct estimation of 
Total cholesterol (TC), and HDL-c levels was done from fasting serum samples employing CHOD-PAP 
method. Triglycerides (TG) were also directly estimated from fasting serum samples employing a 
GPO-PAP method. All lipid estimations were done using RX Imola benchtop clinical chemistry 
Analyzer (Randox Laboratories Ltd). Low and very low density lipoprotein cholesterols (LDL-c and 
VLDL-c) were calculated employing the Friedewald’s formula (Friedewald, Levy, & Fredrickson, 1972), 
i.e. LDL-c = TC–HDL-c–(triglyceride/5) and VLDL-c = 0.20 (TG), respectively.
2.3. Genotyping techniques
The samples were genotyped for these single nucleotide polymorphisms (SNP’s) using polymerase 
chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Genotyping condi-
tions were used as described in previously published literature (Hixson & Powers, 1991; Paul-Hayase 
et al., 1992). Genotypes were determined on the basis of presence or absence of bands on the gel 
photographs. Approximately 10% of samples were repeated randomly to assess the reliability of 
PCR-RFLP methods and genotyping. All genotyping was done without the knowledge of disease sta-
tus. The genotypes were scored independently by two researchers and the allele frequencies were 
calculated by allele counting method.
2.4. Statistical analysis
Statistical analysis was carried out using the computer packages EXCEL and SPSS® for WINDOWS 
softwares (version 16.0; SPSS® Inc, Chicago IL). Independent t-tests were used to analyse differ-
ences between the means of continuous variables. Discrete variables, genotype distribution and 
Hardy–Weinberg equilibrium (HWE) were tested using χ2 test with Yates’s correction. Odds Ratios 
(OR’s) 95% confidence intervals (CI) and associated chi-squares were calculated for genotypes and 
alleles. Haplotype analysis was performed using Arlequin® software (version 3.11) (Excoffier, Laval, 
& Schneider, 2005). Two-tailed p values of <0.05 were considered to be statistically significant.
3. Results
The patient and control groups were age, sex and ethnicity matched (p > 0.05). No significant differ-
ence was observed for dietary habits, though patient group reported a higher number of non-vege-
tarians (46 vs. 39%, p = 0.19, NS).
Statistically significantly differences were observed between the two groups for some conven-
tional risk factors for CAD (Table 1). There were more smokers among patients (34.5%) as opposed 
to in controls (22.0%) (p = 0.007); more hypertensives among patients (28.5%) vs. in controls (16.0%) 
(p = 0.004); higher number of diabetics among patients (24.0%) vs. controls (6.5%) (p < 0.001) and 
16.0% of the patients had a family history of premature CAD compared to controls (6.5%) (p = 0.004) 
(Table 1).
Eighty-one percent of patients (n = 162) were on lipid lowering therapy (at the time of their inclu-
sion), the patient group still had markedly higher mean levels of various serum lipid parameters 
compared to the control group (p < 0.001). Similarly mean levels of TC/HDL and LDL/HDL ratios were 
also significantly higher in patients when compared to controls (p = 0.002) (Data not shown).
Genotype frequencies in patients and controls for all of the studied SNP’s did not differ from that 
expected for Hardy–Weinberg proportions. We found no significant differences in genotype and 
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allele frequencies between patient and control groups for ApoAI-75G > A, ApoC-III 3238C > G (SstI) 
and ApoA-IV 347A > T (Thr347Ser) polymorphisms (p > 0.05), (Table 2). Even after employing addi-
tive, dominant and recessive models, no statistically significant association of these polymorphisms 
with CAD was observed in this population (Table 2) though many odds ratios containing risk alleles 
were above 1.
Haplotype analysis also did not show any statistically significant association of any of the possible 
haplotypes with CAD (p > 0.05) (Table 3), though some of the haplotypes were more frequent in 
patients.
We also assessed the role of all possible genotypic combinations in CAD. Possible genotypic com-
binations in two polymorphisms at a time, revealed that the subjects who have at least one mutant 
allele for the ApoA-I or ApoA-IV genes, are at a comparatively higher risk for CAD than other geno-
typic combinations (p = 0.03, OR = 1.33) (supplementary Table 2). However, we did not find any clear 
cut trend for the same when we examined genotypic combinations among all the three SNP’s 
(p > 0.05) (supplementary Table 2).
We investigated the association of these SNP’s with various lipid traits in patients and controls. We 
chose to assess the trends only for TC, TG and HDL-c values, as they were directly estimated as op-
posed to other traits (e.g. LDL-c, VLDL-c values and TC/HDL and LDL/HDL ratios) which were calcu-
lated values. As expected no difference was seen among the patient sub group owing to the effect 
of the lipid lowering therapy which was ongoing in a large majority of patients (~81%, as discussed 
earlier). On the other hand, after employing additive, dominant and recessive models in the control 
group we found conclusive evidence of the association of the studied SNP’s with lipid traits (Table 4). 
Significantly higher mean HDL-c values were seen among mutants for Apo AI-75G > A 
Table 1. Baseline characteristics in patient/control groups
Abbreviations used: HDL-c—high density lipoprotein cholesterol; LDL-c and VLDL-c—low and very low density 
lipoprotein cholesterol.
*p-value of <0.05 was considered to be statistically significant; !—t test statistics.
CAD patients 
(n = 200)
Controls 
(n = 200)
Odds ratio 
(OR)/t
p-value
Age (years) Mean ± SD 49.65 ± 11.59 48.53 ± 13.38 0.89! 0.37
Males n (%) 169 (84.5%) 163 (81.5%) 1.12 0.50
Smokers n (%) 69 (34.5%) 44 (22.0%) 1.34 0.007*
Non vegetarians n (%) 92 (46.0%) 78 (39.0%) 1.15 0.19
Family history of 
premature CAD
n (%) 32 (16.0%) 13 (6.5%) 1.50 0.004*
Hypertension n (%) 57 (28.5%) 32 (16.0%) 1.39 0.004*
Diabetes mellitus n (%) 48 (24.0%) 13 (6.5%) 1.75 <0.001*
Alcohol consumers n (%) 68 (34.0%) 51 (25.5%) 1.22 0.08
Total cholesterol 
(mg/dl)
Mean ± SD 173.84 ± 43.49 135.22 ± 31.24 10.97! <0.001*
Triglycerides (mg/dl) Mean ± SD 193.99 ± 102.41 140.65 ± 62.19 6.29! <0.001*
HDL-c (mg/dl) Mean ± SD 32.72 ± 13.17 27.73 ± 9.89 4.28! <0.001*
LDL-c (mg/dl) Mean ± SD 105.53 ± 39.92 80.75 ± 24.23 7.50! <0.001*
VLDL-c (mg/dl) Mean ± SD 35.45 ± 14.30 28.13 ± 12.44 5.46! <0.001*
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polymorphism, as confirmed after comparing them using additive and dominant models (p = 0.042 
and 0.019, respectively) (Table 4). G allele carriers for Apo CIII-SstI polymorphism were associated 
with higher TG levels, as evident by significant p values on comparisons using additive (p = 0.002 and 
0.007), dominant (p < 0.001) and recessive models (p = 0.014) (Table 4). Heterozygotes (AT) at Apo 
AIV, Thr347Ser polymorphism had lower mean HDL-c values compared to wild type genotype (AA) 
in additive model (p = 0.012) (Table 4).
Table 2. Apo AI-CIII-AIV gene cluster polymorphisms in CAD patients vs. controls
*p-value of <0.05 was considered to be statistically significant.
CAD patients 
(n = 200)
Controls (n = 200) OR (95% CI) χ2 p-value
Apo AI, −75G → A polymorphism
AA (mutant) 12 (6.0%) 7 (3.5%) 1.28 (0.89–1.83) 0.88 0.35
GA (Heterozygous) 71 (35.5%) 75 (37.5%) 0.96 (0.78–1.18) 0.09 0.75
GG (Wild type) 117 (58.5%) 118 (59.0%) 0.99 (0.81–1.20) 0.01 0.92
AA vs. GG 12/117 07/118 1.27 (0.88–1.83) 0.78 0.38
GA vs. GG 71/117 75/118 0.98 (0.79–1.20) 0.01 0.90
AA + GA vs. GG 
(dominant model)
83/117 82/118 1.01 (0.83–1.23) 0.01 0.92
AA vs. GA + GG 
(recessive model)
12/188 07/193 1.28 (0.89–1.83) 0.88 0.35
Allele A (frequency) 0.24 0.22 1.06 (0.77–1.45) 0.02 0.87
Allele G (frequency) 0.76 0.78
Apo CIII, 3238C → G polymorphism (SstI Polymorphism)
GG (mutant) 21 (10.5%) 20 (10.0%) 1.03 (0.75–1.40) 0.02 0.87
CG (Heterozygous) 74 (37%) 68 (34.0%) 1.07 (0.87–1.30) 0.27 0.60
CC (Wild type) 105 (52.5%) 112 (56.0%) 0.93 (0.77–1.13) 0.36 0.55
GG vs. CC 21/105 20/112 1.05 (0.76–1.47) 0.02 0.87
CG vs. CC 74/105 68/112 1.08 (0.87–1.33) 0.34 0.56
GG + CG vs. CC 
(dominant model)
95/105 88/112 1.07 (0.88–1.30) 0.36 0.55
GG vs. CG + CC 
(recessive model)
21/179 20/180 1.03 (0.75–1.40) 0.02 0.87
Allele G (S2 allele 
frequency)
0.29 0.27 1.05 (0.78–1.42) 0.02 0.87
Allele C (S1 allele 
frequency)
0.71 0.73
Apo AIV, 347A → T polymorphism (Thr347Ser Polymorphism)
TT (mutant) 30 (15.0%) 19 (9.5%) 1.26 (0.99–1.62) 2.33 0.13
AT (Heterozygous) 81 (40.5%) 75 (37.5%) 1.06 (0.87–1.30) 0.26 0.61
AA (Wild type) 89 (44.5%) 106 (53.0%) 0.84 (0.69–1.03) 2.56 0.10
TT vs. AA 30/89 19/106 1.34 (1.02–1.76) 3.21 0.07
AT vs. AA 81/89 75/106 1.14 (0.92–1.41) 1.13 0.28
TT + AT vs. AA 
(dominant model)
111/89 94/106 1.19 (0.97–1.45) 2.56 0.11
TT vs. AT + AA 
(recessive model)
30/170 19/181 1.26 (0.99–1.62) 2.33 0.13
Allele T (347Ser allele 
frequency)
0.35 0.28 1.17 (0.88–1.55) 0.83 0.36
Allele A (Thr347 allele 
frequency)
0.65 0.72
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Table 3. Haplotype analysis for association with CAD
*p-value of <0.05 was considered to be statistically significant.
**The order of SNPs within each haplotype is Apo AI (-75G/A polymorphism); Apo CIII (SSTL polymorphism); Apo AIV 
(T347S polymorphism).
Haplotypes** Patients (n = 200) Controls (n = 200) OR 95% CI p-value
A-C-A 83 (20.75%) 83 (20.75%) 1 0.71–1.40 1
G-C-T 32 (8.00%) 24 (6.00%) 1.36 0.79–2.35 0.33
G-C-A 164 (41.00%) 183 (45.75%) 0.82 0.62–1.09 0.20
A-C-T 5 (1.25%) 2 (0.5%) 2.52 0.48–13.06 0.45
G-G-T 97 (24.25%) 83 (20.75%) 1.22 0.88–1.70 0.27
A-G-T 7 (1.75%) 4 (1.00%) 1.76 0.51–6.07 0.54
G-G-A 12 (3.00%) 21 (5.25%) 0.56 0.27–1.15 0.15
Table 4. Lipid levels among disease free controls according to different genetic models
n Serum lipid levels 
Mean ± SD (SEM)
95% CI (diff) p-value
Apo AI, -75G > A polymorphism
AA vs. GG 7 vs. 118
TC (mg/dl) 152.14 ± 45.26 (17.11) vs. 
132.47 ± 30.24 (2.78)
−22.22 to 61.56 0.298
TG (mg/dl) 147.71 ± 51.24 (19.37) vs. 
135.59 ± 56.48 (5.20)
−35.45 to 59.69 0.565
HDL-c (mg/dl) 34.29 ± 8.48 (3.21) vs. 
27.19 ± 9.58 (0.88)
−0.78 to 14.96 0.071
GA vs. GG 75 vs. 118
TC (mg/dl) 137.96 ± 31.09 (3.59) vs. 
132.47 ± 30.24 (2.78) 
−3.49 to 14.46 0.229
TG (mg/dl) 147.49 ± 65.20 (7.53) vs. 
135.59 ± 56.48 (5.20)
−6.19 to 29.99 0.196
HDL-c (mg/dl) 30.23 ± 27.19 (1.18) vs. 27.19 vs. 
9.58 (0.88)
0.12 to 5.95 0.042*
AA + GA vs. GG (dominant model) 82 vs. 118
TC (mg/dl) 139.07 ± 32.41 (3.58) vs. 
132.47 ± 30.24 (2.78)
−2.26 to 15.65 0.142
TG (mg/dl) 147.51 ± 63.86 (7.05) vs. 
135.59 ± 56.48 (5.20)
−5.38 to 29.22 0.176
HDL-c (mg/dl) 30.57 ± 10.11 (1.12) vs. 
27.19 ± 9.58 (0.88)
0.57 to 6.19 0.019*
AA vs. GA + GG (recessive model) 7 vs. 193
TC (mg/dl) 152.14 ± 45.26 (17.11) vs. 
134.61 ± 30.61 (2.20)
−24.34 to 59.41 0.347
TG (mg/dl) 147.71 ± 51.24 (19.37) vs. 
140.22 ± 60.14 (4.33)
−39.99 to 54.98 0.717
HDL-c (mg/dl) 34.28 ± 8.48 (3.21) vs. 
28.37 ± 9.92 (0.71)
−1.95 to 13.77 0.117
Apo CIII, 3238C > G polymorphism (SstI Polymorphism)
GG vs.CC 20 vs. 112
TC (mg/dl) 138.00 ± 27.60 (6.17) vs. 
134.79 ± 30.44 (2.88)
−10.73 to 17.16 0.641
TG (mg/dl) 169.00 ± 49.54 (11.08) vs. 
127.70 ± 56.73 (5.36) 
16.12 to 66.48 0.002*
HDL-c (mg/dl) 27.70 ± 9.04 (2.02) vs. 
29.30 ± 10.22 (0.97)
−6.19 to 2.98 0.480
(Continued)
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n Serum lipid levels 
Mean ± SD (SEM)
95% CI (diff) p-value
CG vs. CC 68 vs. 112
TC (mg/dl) 135.12 ± 33.84 (4.10) vs. 
134.79 ± 30.44 (2.88)
−9.58 to 10.24 0.947
TG (mg/dl) 153.15 ± 62.43 (7.57) vs. 
127.70 ± 56.73 (5.36)
7.10 to 43.80 0.007*
HDL-c (mg/dl) 27.65 ± 9.70 (1.18) vs. 
29.30 ± 10.22 (0.97)
−4.66 to 1.35 0.278
GG + CG vs.CC (dominant model) 88 vs. 112
TC (mg/dl) 135.77 ± 32.40 (3.45) vs. 
134.79 ± 30.44 (2.88)
−7.88 to 9.86 0.826
TG (mg/dl) 156.75 ± 59.85 (6.38) vs. 
127.70 ± 56.73 (5.36)
12.61 to 45.50 <0.001*
HDL-c (mg/dl) 27.66 ± 9.50 (1.01) vs. 
29.30 ± 10.22 (0.97)
−4.40 to 1.12 0.241
GG vs. CG + CC (recessive model) 20 vs. 180
TC (mg/dl) 138.00 ± 27.60 (6.17) vs. 
134.91 ± 31.68 (2.36)
−10.52 to 16.70 0.644
TG (mg/dl) 169.00 ± 49.54 (11.08) vs. 
137.31 ± 60.06 (4.48)
7.11 to 56.26 0.014*
HDL-c (mg/dl) 27.70 ± 9.04 (2.02) vs. 
28.68 ± 10.03 (0.75)
−5.42 to 3.47 0.654
Apo AIV, 347A > T polymorphism (Thr347Ser Polymorphism)
TT vs. AA 19 vs. 106
TC (mg/dl) 138.89 ± 26.58 (6.10) vs. 
135.07 ± 30.44 (2.96) 
−10.07 to 17.73 0.577
TG (mg/dl) 154.05 ± 57.60 (13.21) vs. 
133.65 ± 58.08 (5.64)
−9.19 to 49.99 0.168
HDL-c (mg/dl) 31.58 ± 10.32 (2.37) vs. 
29.77 ± 10.30 (1.00)
−3.49 to 7.10 0.489
AT vs. AA 75 vs. 106
TC (mg/dl) 134.51 ± 33.69 (3.89) vs. 
135.07 ± 30.44 (2.96)
−10.21 to 9.09 0.909
TG (mg/dl) 146.69 ± 62.08 (7.17) vs. 
133.65 ± 58.08 (5.64)
−4.98 to 31.06 0.155
HDL-c (mg/dl) 26.13 ± 8.82 (1.02) vs. 
29.77 ± 10.30 (1.00)
−6.46 to −0.82 0.012*
TT + AT vs. AA (dominant model) 94 vs. 106
TC (mg/dl) 135.39 ± 32.29 (3.33) vs. 
135.07 ± 30.44 (2.96)
−8.46 to 9.11 0.941
TG (mg/dl) 148.18 ± 60.97 (6.29) vs. 
133.65 ± 58.08 (5.64)
−2.13 to 31.19 0.087
HDL-c (mg/dl) 27.23 ± 9.34 (0.96) vs. 
29.77 ± 10.30 (1.00)
−5.28 to 0.20 0.069
TT vs. AT + AA (recessive model) 19 vs. 181
TC (mg/dl) 138.89 ± 26.58 (6.10) vs. 
134.83 ± 31.73 (2.36)
−9.44 to 17.56 0.540
TG (mg/dl) 154.05 ± 57.60 (13.21) vs. 
139.05 ± 59.95 (4.46)
−13.90 to 43.90 0.294
HDL-c (mg/dl) 31.58 ± 10.32 (2.37) vs. 
28.27 ± 9.85 (0.73)
−1.83 to 8.46 0.195
Table 4. (Continued)
*p-value of <0.05 was considered to be statistically significant.
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4. Discussion
The present study was a prospective, single centre, case-control study to assess the risk for CAD and 
investigate the association with various lipid traits in subjects with genetic variations in the ApoA-I, 
ApoC-III and ApoA-IV genes among a sample population of North Indian ethnicity. This study was 
conducted in SGPGIMS: a premier, public sector, tertiary care, teaching hospital situated in Lucknow, 
Uttar Pradesh (UP). UP is the largest state in northern India with a total population of approximately 
199 million. The data derived from the present study represents the population from UP, which pri-
marily belong to the north Indian ancestry and also adds to the existing literature on the subject 
from this geo-ethnic region.
4.1. ApoAI-75G > A polymorphism
As discussed earlier, Apolipoprotein A-I is the major protein constituent of HDL-c and plays a crucial 
role in reverse cholesterol transport. Sufficient published evidence exists, which negatively associates 
plasma levels of both ApoA-I and HDL-c as independent risk factors for CAD (Ascaso et al., 2004; Heng, 
Low, & Saha, 2001). ApoAI-75G > A polymorphism influences the normal expression of Apo AI gene 
has also been shown to influence plasma levels of various lipid traits (Wang et al., 1996; Xu et al., 1994).
Some studies have shown the association of “A” allele (minor/mutant allele) carriers with signifi-
cantly higher TG levels (Souverein, Jukema, Boekholdt, Zwinderman, & Tanck, 2005; Xu et al., 1994), 
whilst others have shown its no association with TG (Kamboh et al., 1999; Larson et al., 2002). In the 
present study, although we found higher mean TG levels amongst “A” allele carriers (in controls), but 
the difference were non-significant to substantiate above findings (Table 4). On the other hand, some 
other studies like the present study have reported a significant association of “A” allele with elevated 
levels of HDL-c (Paul-Hayase et al., 1992; Pagani et al., 1990). This dual role of “A” allele is more of a 
paradox, as it is well established that higher TG levels is a risk factor for CAD whereas higher levels of 
HDL-c is protective against the disease. Hypothetically, if we assume that if the presence of “A” allele 
in an individual raises the serum levels of both HDL-c and TG, owing to the antagonistic nature of 
both, it would not affect the fate of the outcome, i.e. CAD. This hypothesis could qualify as a plausible 
explanation for a similar outcome in the present study, where trends for both, increased levels of TG 
and HDL-c were seen among carriers of “A” allele (among controls) but no hint of any association of 
ApoAI-75G > A polymorphism with CAD was seen, even after employing different genetic models.
Our results are in contradiction with another study which reported a positive association between 
Apo A1-75G > A polymorphism and CAD among subjects from Punjab, Haryana and Chandigarh 
(Poduri, Khullar, Bahl, Sharma, & Talwar, 2009). The possible reasons for this contradiction are un-
clear and could be different geographical regions, uneven distribution of patients and controls in 
these studies, It must be stressed that even among populations of similar ethnicity and gene pool, 
environmental factors such as diet, stress and physical inactivity compound to an individual’s com-
posite risk for CAD in inexplicable proportions. A multi-centric study among North Indians with a 
larger sample size is warranted to answer this question definitively. In another study from Northwest 
India, a different locus (APOA1, Pst1 polymorphism) was also not found to be associated with CAD 
(Singh et al., 2007, 2008) suggesting limited role of this locus in CAD diagnosis in this region.
4.2. ApoCIII 3238C > G polymorphism
ApoC-III is predominantly synthesized in liver and intestine and is present on very low density lipo-
proteins (VLDLs) and chylomicron remnants; and to a lesser extent on high density lipoproteins 
(HDLs) (Breslow, 1995). The function of ApoCIII is not completely understood although it has been 
shown in vitro, to inhibit lipoprotein lipase (LPL) which limits the rate of TG hydrolysis, resulting in the 
delayed catabolism of TG-rich particles (Wang, McConathy, Kloer, & Alaupovic,1985). Furthermore, it 
also decreases ApoE-mediated remnant removal by displacement of ApoE from the VLDL particles 
in vivo (Aalto-Setälä et al., 1996). The presence of a polymorphic SstI site {S2(G) allele} in the 3′ un-
translated region (UTR) (3238C > G) has been associated with elevated TG levels in various ethnic 
populations (Chhabra et al., 2002; Ordovas et al., 2002; Singh et al., 2007, 2008; Zeng et al., 1995).
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In the present study, although we found clear cut association of genotypes (among controls) car-
rying either one or both mutant (G) alleles with higher TG levels, confirmed by employing codomi-
nant, dominant and recessive models of inheritance (p < 0.01), but frequencies of various genotypes/
alleles among CAD patient and control groups were found to be comparable (p > 0.05), indicating no 
association with CAD (Tables 2–4). Our results are in concordance with other studies among North 
Indians (Chhabra et al., 2004; Singh et al., 2007, 2008) who reported no association of S2(G) allele 
with CAD, while being associated with significantly higher levels of TG. Contrary to the results re-
ported from northern Indian populations (including our study), a recent study by Kumar and col-
leagues (AshokKumar et al., 2010) reported S2(G) allele to be significantly associated with CAD 
among South Indians. This contradiction may be because of ethnic differences, which makes South 
Indians more prone to CAD. This difference is reflected in the CAD prevalence rates also among 
South Indians which are much higher than that found in North Indians (Begom & Singh, 1995). Also 
since CAD is a multifactorial disease, this difference could be a result of interplay between various 
risk factors (both genetic and environmental), which very often provide a variety of results in sub-
jects of different ethnicities. Initially triglyceride levels were considered to be an independent risk 
factor for CAD, but there is now increasing evidence that higher triglyceride levels could be more of 
a synergistic risk factor for CAD. It is well known that clustering of risk factors can effect in height-
ened chance of developing CAD in an individual, e.g. the end effects, i.e. composite risk of CAD is 
exponentially increased in the patients with “lipid triad”, i.e. Low HDL-c values and high LDL-c and TG 
values. Since this SNP effects only the serum concentrations of TG, which as we said, is a poor risk 
factor for CAD is probably not able to decisively affect the pathogenesis of CAD.
4.3. ApoA-IV Thr347Ser polymorphism
Apolipoprotein A-IV (Apo AIV) is a plasma glycoprotein synthesized in the enterocytes of the small 
intestine during fat absorption as a constituent of nascent chylomicrons. As evident by several in 
vitro studies, ApoA-IV is involved in several steps of the reverse cholesterol transport pathway, which 
removes cholesterol from peripheral cells and transports it back to the liver. Scientific evidence ex-
ists, which suggests the participation of ApoA-IV in the binding and uptake of HDL by hepatocytes 
(Dvorin, Gorder, Benson, & Gotto, 1986). Moreover, ApoA-IV modulates the activation of lipoprotein 
lipase (Goldberg, Scheraldi, Yacoub, Saxena, & Bisgaier, 1990) and the cholesteryl ester transfer pro-
tein (CETP)-mediated transfer of cholesteryl esters from HDL to low-density lipoprotein (LDL), as evi-
dent from several tissue culture studies (Guyard-Dangremont, Lagrost, & Gambert, 1994). Thus 
extrapolated effects of several roles of ApoA-IV may represent it as an anti-atherogenic factor. This 
hypothesis is supported by in vivo studies which have demonstrated an anti-atherogenic role for 
ApoA-IV (Duverger et al., 1996; Cohen et al., 1997). In a couple of studies, mice that overexpress hu-
man or mouse apoAIV and were subjected to fat rich diets demonstrated a significant reduction of 
aortic atherosclerotic lesions when compared to control mice. Several polymorphisms in the ApoA-
IV gene have been shown to effect either an increase or a decrease in various lipid traits. The TT 
(homozygous mutant) genotype has been has been linked to increased risk of CAD along with lower 
serum concentrations of Apolipoprotein AIV among subjects from UK (Wong et al., 2003). In the 
present study we although found a trend of higher risk for CAD among carriers of T allele, with more 
OR in homozygous mutants (OR = 1.34, p = 0.07) than in the heterozygous ones (OR = 1.14, p = 0.28) 
but the results of comparisons were non-conclusive as evident by non-significant p values, even af-
ter employing different genetic models (Table 2).
Only some studies in the past have definitively associated this SNP with cholesterol values (Fisher, 
Burke, Nicaud, Ehnholm, & Humphries, 1999; Saha, Wang, Vasisht, & Kamboh, 1997) while other stud-
ies have failed to do so (Wang et al., 2003). The only published study among North Indians has reported 
lower levels of LDL-c associated with T allele (Saha et al., 1997). On the contrary, present study did not 
find any association LDL-c levels (among control subjects) even after using different genetic models. 
The factor that caused different results in these two studies could be the subject selection criteria. 
While both control cohorts of subjects were free of overt CAD, sampling in our study was performed in 
a fasting state as opposed the sampling in a non-fasting state in the previous study (Saha et al., 1997). 
Since Apo A-IV has a very short plasma residence time (Ghiselli, Krishnan, Beigel, & Gotto, 1986), it is 
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more relevant in lipoprotein metabolism regulation in the postprandial state rather than in the fasting 
state where plasma Apo A-IV levels quickly fall to lower levels (Sherman & Weinberg,1988) which is 
turn possibly recedes serum LDL-c levels. This factor could have possibly caused the observed non-as-
sociation of Apo AIV Thr347Ser polymorphism with LDL-c levels in the present study. Also, we in the 
present study have not studied the possible interaction of this SNP with another well-known SNP at 
codon 360 in the Apo AIV gene. It has been shown by Saha and colleagues in a two site haplotype 
analysis that there can be as much as twice the amount of LDL-c variation between the single site 
(codon 347) polymorphism and the double site (codon 347 and 360) polymorphism (i.e. 2.6 vs. 5.2% 
respectively) of the Apo AIV gene (Saha et al., 1997). Our study was however able to show lower levels 
of HDL-c among heterozygous mutants (AT) when compared to that in wild genotype (AA). This effect 
was however nullified as evident of the results of the comparison employing the dominant model, thus 
indicating that the positive association could be a statistical anomaly.
As per our knowledge, this is the first study among North Indians which has investigated the as-
sociation of Thr347Ser polymorphism in the Apo AIV gene with CAD. Thus, from the present data, it 
would be safe to conclude that unlike the other ethnic populations of the world (especially Caucasians), 
North Indians tend to show no association of this SNP with CAD or fasting plasma cholesterol levels. 
However, this subject needs to be further investigated which warrants functional studies.
4.4. Genotypic/haplotypic combinations and CAD
We also assessed the role of all possible genotypic combinations arising due to Apolipoprotein AI 
(-75G > A), CIII-SstI and AIV Thr347Ser polymorphism with CAD. Interestingly using double geno-
type analysis we found that the frequency of combinations of Apo AI and AIV mutants were signifi-
cantly higher in patients as opposed to controls, indicating that subjects carrying even one mutant 
alleles of both these polymorphisms carry at least 1.3-fold higher risk of developing CAD (p = 0.03, 
OR = 1.33, 95%CI = 1.06–1.65) (supplementary Table 2). Interestingly similar association was not 
seen in triple genotype analysis (supplementary Table 2). This association may well have been a 
“matter of chance”, as demonstrated by distribution of haplotype combinations which showed no 
significant difference among CAD patients and controls negating the role of haplotypic combina-
tions of the selected polymorphisms in disease pathogenesis in the study population (Table 3).
Thus we prescribe a wholesome approach while calculating the composite risk of an individual. 
Genetic association studies may provide a better understanding of a “new factor”, adding to the 
knowledge of already known risk factors for a particular disease. Considering these conventional and 
newer risk factors together in risk assessment of an individual could ultimately help us in the future 
to correctly predict the onset of multifactorial diseases such as CAD.
5. Conclusion
To conclude, we have demonstrated association of these SNP’s with various cholesterol traits 
(among control population), but it seems that their extrapolated effect do not decisively/signifi-
cantly contribute in the pathogenesis of CAD. Role of genotypic combinations of these SNP’s in the 
pathogenesis of CAD is still unclear and remains to be further evaluated. This suggests that there 
should be more data on these markers from different parts of India.
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